Comparative Pharmacology
Head-to-head clinical analysis: ERGOLOID MESYLATES versus WIGRAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERGOLOID MESYLATES versus WIGRAINE.
ERGOLOID MESYLATES vs WIGRAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
WIGRAINE is a combination product containing ergotamine, a vasoconstrictor that acts as an agonist at serotonin (5-HT1B/1D) and alpha-adrenergic receptors, and caffeine, which enhances ergotamine absorption and provides additional vasoconstriction.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
For acute migraine: 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
None Documented
None Documented
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Ergotamine: ~2-3 hours (terminal). Clinical context: short half-life necessitates frequent dosing for acute migraine relief.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Primarily hepatic metabolism; renal excretion of metabolites. ~90% urinary, ~10% fecal.
Category A/B
Category C
Ergot Alkaloid
Ergot Alkaloid